DelveInsight’s, “Gastroesophageal Reflux Disease Pipeline Insight 2023” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Gastroesophageal Reflux Disease (GERD) pipeline landscape. It covers the Gastroesophageal Reflux Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gastroesophageal Reflux Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Gastroesophageal Reflux Disease Pipeline Report

• DelveInsight’s Gastroesophageal Reflux Disease pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Gastroesophageal Reflux Disease treatment.
• The leading companies working in the Gastroesophageal Reflux Disease Market include Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, and others.
• Promising Gastroesophageal Reflux Disease Pipeline Therapies in the various stages of development include rabeprazole, Vonoprazan, Pumosetrag, Omeprazole, and others.
• November 2023: Phathom Pharmaceuticals Inc. announced a study of Phase 1 clinical trials for Vonoprazan. The aim of this study is to evaluate the pharmacokinetic (PK) profile of vonoprazan (10 or 20 mg once daily [QD]) in children ≥ 6 to < 12 years of age who have symptomatic Gastroesophageal Reflux Disease (GERD). A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Children Aged ≥ 6 to < 12 Years Who Have Symptomatic Gastroesophageal Reflux Disease.
• November 2023: Daewoong Pharmaceuticals Co. Ltd announced a study of Phase 3 clinical trials for DWP14012 20mg. This study is designed to determine the efficacy and safety of DWP14012 compared to a placebo following a once-daily oral dose of DWP14012 at 20 mg, 40 mg, or placebo for 4 weeks in patients with NERD. A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3, Therapeutic Confirmatory Clinical Trial to Evaluate the Efficacy and Safety of DWP14012 in Patients With Non-erosive Gastroesophageal Reflux Disease.
• October 2023: Braintree Laboratories announced a study of Phase 3 clinical trials for BLI5100. The objective of this study is to evaluate the safety of up to 12 months (52 weeks) of once daily oral administration of BLI5100 in patients with non-erosive reflux disease (NERD) or healed erosive esophagitis (EE). A Study to Evaluate the Long-Term Safety of BLI5100 in Patients with Gastroesophageal Reflux Disease.

 

Request a sample and discover the recent advances in Gastroesophageal Reflux Disease Treatment Drugs @ Gastroesophageal Reflux Disease Pipeline Report

 

In the Gastroesophageal Reflux Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Gastroesophageal Reflux Disease Overview

Gastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. It is one of the most commonly diagnosed digestive disorders in the US with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life. Currently, there is no known cause to explain the development of GERD.

 

Find out more about Gastroesophageal Reflux Disease Therapeutics Assessment @ Gastroesophageal Reflux Disease Preclinical and Discovery Stage Products

 

Gastroesophageal Reflux Disease Emerging Drugs Profile

• X842: Cinclus Pharma
• Zastaprazan: Onconic Therapeutics

 

Gastroesophageal Reflux Disease Pipeline Therapeutics Assessment

There are approx. 10+ key companies which are developing the therapies for Gastroesophageal Reflux Disease (GERD). The Gastroesophageal Reflux Disease companies which have their Gastroesophageal Reflux Disease (GERD) drug candidates in the most advanced stage, i.e. Phase III include, Onconic Therapeutics.

 

DelveInsight’s Gastroesophageal Reflux Disease Pipeline report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Gastroesophageal Reflux Disease (GERD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Gastroesophageal Reflux Disease Pipeline Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Learn more about the emerging Gastroesophageal Reflux Disease Pipeline Therapies @ Gastroesophageal Reflux Disease Clinical Trials Assessment

 

Scope of the Gastroesophageal Reflux Disease Pipeline Report

• Coverage- Global
• Gastroesophageal Reflux Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Gastroesophageal Reflux Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Gastroesophageal Reflux Disease Companies- include Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, and others.
• Gastroesophageal Reflux Disease Pipeline Therapies- Rabeprazole, Vonoprazan, Pumosetrag, Omeprazole, and others.

 

Dive deep into rich insights for new drugs for Gastroesophageal Reflux Disease Treatment, Visit @ Gastroesophageal Reflux Disease Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Gastroesophageal Reflux Disease (GERD): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Gastroesophageal Reflux Disease (GERD) – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Zastaprazan: Onconic Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. X842: Cinclus Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IN-C005: HK inno.N
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Gastroesophageal Reflux Disease (GERD) Key Companies
21. Gastroesophageal Reflux Disease (GERD) Key Products
22. Gastroesophageal Reflux Disease (GERD)- Unmet Needs
23. Gastroesophageal Reflux Disease (GERD)- Market Drivers and Barriers
24. Gastroesophageal Reflux Disease (GERD)- Future Perspectives and Conclusion
25. Gastroesophageal Reflux Disease (GERD) Analyst Views
26. Gastroesophageal Reflux Disease (GERD) Key Companies
27. Appendix

 

For further information on the Gastroesophageal Reflux Disease Pipeline therapeutics, reach out to Gastroesophageal Reflux Disease Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment